Highlights
1 patent
About
Next Generation of Metabolic and Inflammatory Therapeutics
Galmed Pharmaceuticals is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. The company is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.
Identity
| Name | Galmed Pharmaceuticals |
|---|---|
| Slug | galmed-pharmaceuticals |
| Type / kind | startup |
| Crunchbase ID | galmed-pharmaceuticals |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN725ZAKDA |
Status
| Status | active |
|---|---|
| Status reason | Public on NASDAQ on Mar, 2014<br> |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | 16 Tiomkin Street, Tel Aviv |
Web & social
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business models
B2B
Tags
metabolic-diseasedrug-discoverypharmaceuticalsmicrobiomebiopharmaceuticaloral-drugscrohn-s-diseasediabetespharma-companiesinflammatory-diseases
Funding
| Total raised | $150.3M |
|---|---|
| Current stage | Public |
| Market cap | $4.1M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}